Attenuation of the opioid withdrawal syndrome by inhibitors of n

Details Attenuation of the opioid withdrawal syndrome by inhibitors of n Attenuation of the opioid withdrawal syndrome by inhibitors of n

1991-09-13

1993-07-06

Friedman, S. J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

514561, A61K 3124, A61K 31195

Patent

active

052254402

ABSTRACT:
A method of attenuating the symptoms of opioid withdrawal in a human or animal subject comprises administering to the subject an effective opioid withdrawal symptom attenuating amount of an inhibitor of nitric oxide synthase (NOS) for a period of time effective to attenuate such symptoms upon opioid withdrawal. NOS inhibitors useful in the present method include, for example, L-N.sup.G -nitroarginine, esters of L-N.sup.G -nitroarginine, L-N.sup.G -monomethylarginine, L-N.sup.G -benzylarginine, L-N.sup.G -aminoarginine, iminoethylornithine, and pharmaceutically acceptable salts thereof. These compounds can be used alone or in combination, in conjunction with conventional drugs, such as .alpha..sub.2 -adrenoceptor agonists, mixed agonist-antagonist opioids, and NMDA antagonists, to attenuate the symptoms of opioid withdrawal. Effective doses of NOS inhibitors range from about 1 .mu.g/kg/day to about 30 mg/kg/day, administered over the course of about 1 hour to about six days, followed by opioid withdrawal.

REFERENCES:
Dwyer et al (1991) Biochemical and Biophysical Research Communications 176(3): 1136-1141.
J. H. Jaffe, Goodman and Gilman's Pharmacological Basis of Therapeutics, Ch. 22, pp. 560-561 (1991).
Fudala et al (1990) Clin. Pharmacol. Thera. 47(4):525-534.
J. Garthwaite (1991) TINS 14(2):60-67.
McCall et al (1991) Br. J. Pharmacol. 102:234-238.
Olney et al (1989) Science 244:1360-1362.
Preprint of Rasmussen et al (1991) European Journal of Pharmacology 197: 9-16.
Trujillo et al (1991) Science 251:85-87.

Affiliated with

Also associated with

Rating

Attenuation of the opioid withdrawal syndrome by inhibitors of n does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Attenuation of the opioid withdrawal syndrome by inhibitors of n, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuation of the opioid withdrawal syndrome by inhibitors of n will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1689852